Asthma Clinical Trial
— SPIRITUSOfficial title:
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Verified date | May 2018 |
Source | Vaxart |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo. The objectives are to obtain safety and efficacy data in moderate to severe asthmatic patients, aged 18 to 75 years at risk of loss of asthma control due to presumptive Human Rhinovirus infection.
Status | Completed |
Enrollment | 455 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Moderate and severe male and female asthma subjects aged 18 to 75 years, (inclusive) 2. Established clinical history of Asthma for at least 1 year, and a history within the last 14 months (prior to screening) of asthma exacerbation due to presumed viral respiratory infections, which required asthma rescue medication treatment. 3. The asthma subjects will be currently taking at least medium-dose or high-dose ICS defined as fluticasone at a dosage of at least >264 µg daily and may be taking other asthma medication preparations. The asthma subjects' medication regimen must be stable for at least 4 weeks before screening. 4. Subjects will have at screening or within the last year, documented variable airway obstruction as indicated by an increase in FEV1 (>12%) to short acting bronchodilator, or positive methacholine challenge, or positive histamine challenge (PC20 <8 mg/mL). 5. Upon presentation to the clinic with cold symptoms, subjects will be required to be randomized and treated within 48 hours of symptom onset and will be qualified for presumptive rhinovirus infection by: 1. clinical exam and the presence of each of the following Day 1 WURSS-21 symptoms at a severity of 2 or greater: runny nose, sore throat, scratchy throat. 2. subjects must also have a minimum total symptom score on the Day 1 WURSS-21 of 20 points. 3. subjects will be further qualified as presumptively infected with HRV via exclusion of subjects having significant fever and exclusion of subjects testing positive for influenza via Rapid Antigen Test. Exclusion Criteria: 1. Subjects presenting to the clinic with a current severe asthma exacerbation will be excluded from randomization, as well as any subject with an additional underlying respiratory medical condition other than asthma such as COPD, cystic fibrosis, or chronic sinusitis, or any other uncontrolled clinically significant disease which would interfere with the assessment outcomes or subject safety. 2. Female subjects must not be pregnant or breastfeeding. Females of childbearing potential must be willing to utilize a double barrier method of contraception, as defined in this protocol, regardless of any hormonal contraception they may be concomitantly receiving. 3. Male subjects must agree to use a method of birth control defined in this protocol. 4. The use of medications known to moderately or severely inhibit or induce cytochrome (CYP) 3A4 and 2C19 enzymes, or those known to be sensitive substrates (with a narrow therapeutic range) of these CYPs are restricted. |
Country | Name | City | State |
---|---|---|---|
Bulgaria | Biota Investigational site | Ruse | |
Bulgaria | Biota Investigational site | Sofia | |
Bulgaria | Biota Investigational site | Sofia | |
Bulgaria | Biota Investigational site | Sofia | |
Bulgaria | Biota Investigational site | Sofia | |
Bulgaria | Biota Investigational site | Stara Zagora | |
Czechia | Biota Investigational site | Jindrichuv Hradec | |
Czechia | Biota Investigational site | Kyjov | |
Czechia | Biota Investigational site | Lovosice | |
Czechia | Biota Investigational site | Melnik | |
Czechia | Biota Investigational site | Prague | |
Czechia | Biota Investigational site | Rokycany | |
Georgia | Biota Investigational site | Tbilisi | |
Georgia | Biota Investigational site | Tbilisi | |
Georgia | Biota Investigational site | Tbilisi | |
Poland | Biota Investigational site | Bialystok | |
Poland | Biota Investigational site | Kielce | |
Poland | Biota Investigational site | Krakow | |
Poland | Biota Investigational site | Lodz | |
Poland | Biota Investigational site | Lublin | |
Poland | Biota Investigational site | Skierniewice | |
Poland | Biota Investigational site | Warsaw | |
Poland | Biota Investigational site | Wroclaw | |
Poland | Biota Investigational site | Wroclaw | |
Romania | Biota Investigational site | Brasov | |
Romania | Biota Investigational site | Bucharest | |
Romania | Biota Investigational site | Craiova | |
Romania | Biota Investigational site | Mures | |
Romania | Biota Investigational site | Sibiu | |
United States | Biota Investigational site | Albuquerque | New Mexico |
United States | Biota Investigational site | Bakersfield | California |
United States | Biota Investigational site | Baltimore | Maryland |
United States | Biota Investigational site | Bellevue | Nebraska |
United States | Biota Investigational site | Birmingham | Alabama |
United States | Biota Investigational site | Centennial | Colorado |
United States | Biota Investigational site | Denver | Colorado |
United States | Biota Investigational site | Fargo | North Dakota |
United States | Biota Investigational site | Flagstaff | Arizona |
United States | Biota Investigational site | Greenfield | Wisconsin |
United States | Biota Investigational site | Hialeah | Florida |
United States | Biota Investigational site | Houston | Texas |
United States | Biota investigational site | Las Vegas | Nevada |
United States | Biota Investigational site | Los Angeles | California |
United States | Biota Investigational site | Medford | Oregon |
United States | Biota Investigational site | Middleburg | Ohio |
United States | Biota Investigational site | New Port Richey | Florida |
United States | Biota Investigational site | Ocean City | New Jersey |
United States | Biota Investigation site | Oklahoma City | Oklahoma |
United States | Biota Investigational site | Orange | California |
United States | Biota Investigational site | Oviedo | Florida |
United States | Biota Investigation site | Palmetto Bay | Florida |
United States | Biota Investigational site | Portland | Oregon |
United States | Biota Investigational site | Raleigh | North Carolina |
United States | Biota Investigational site | Rockville Centre | New York |
United States | Biota Investigational site | Saint Louis | Missouri |
United States | Biota Investigational Site | San Jose | California |
United States | Biota Investigational site | Seattle | Washington |
United States | Biota Investigational site | Stockton | California |
United States | Biota Investigational site | Tallahassee | Florida |
United States | Biota Investigational site | Toledo | Ohio |
United States | Biota Investigational site | Twin Falls | Idaho |
United States | Biota Investigational site | Warwick | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
Biota Pharmaceuticals, Inc. |
United States, Bulgaria, Czechia, Georgia, Poland, Romania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Asthma Control Questionnaire-6 (ACQ-6) | Least Square (LS) mean change from baseline (Day 1) to Study Day 14 in ACQ-6 total score | Baseline (Day 1) to Study Day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|